CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 71 enrolled
Drug / intervention
eletriptandrug
Likely dose
Eletriptan 20 mg orally three times a day for 6 daysAI-extracted
Key inclusion· 2
  • ✓Age 18-45 years old
  • ✓Healthy menstruating female
Key exclusion· 1
  • ✕Cardiac or other conditions that preclude eletriptan use

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00259649
NCT00259649Phase 4Completed
CompareCT.gov

Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax

University of Pittsburgh·interventional·Posted Nov 29, 2005·Updated Jul 4, 2011

In Brief

A Phase 4 clinical trial evaluating eletriptan for Migraine. Completed, enrolled 71 participants across 1 site.

Detailed Summary

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 29, 2005
Enrollment StartAug 1, 2004
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 20.6 years ago

Interventions

eletriptandrug

oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days